Keir Starmer faces calls from MPs to scrap a controversial healthcare deal dubbed the “Trump tax” and redirect funds towards addressing the longstanding issues in the UK’s social care system. The Liberal Democrats have criticized the Prime Minister for allegedly yielding to pressure from the US President in striking a new trade agreement that experts project could inflate pharmaceutical costs by £3 billion annually. However, the government refutes this estimate, emphasizing the benefits of the deal, including securing zero tariffs on pharmaceuticals from the US, a move lauded as unique on a global scale.
While defending the agreement, the government is also under mounting pressure to accelerate reforms in social care. Recent analysis reveals that over 4.3 million days were spent in hospitals by patients who could have been discharged if adequate care provisions were in place by 2024/25. Deputy leader of the Liberal Democrats, Daisy Cooper, criticized Starmer for prioritizing payments to the White House over addressing the pressing social care crisis, urging immediate action and a clear stance on the matter.
Despite the government’s announcement of a bipartisan commission on social care in January 2021, the commission has convened only once since its inception, drawing criticism for delays in implementing necessary reforms. The Labour Party had pledged to establish a National Care Service before the 2024 general election, with a commission led by Baroness Louise Casey anticipated to present initial recommendations this year and final proposals by 2028.
Amid concerns raised by The Lancet journal about the UK-US agreement potentially increasing drug costs by £3 billion annually, the government maintains its stance on safeguarding supplies and securing advantageous terms for the UK’s medical technology exports. Dismissing the projected cost hike, a government spokesperson emphasized that frontline NHS services will not face cuts to facilitate the deal, underscoring the investment’s importance in bolstering the NHS and life sciences sector.
In response to criticisms, the government highlighted ongoing efforts to address delays in hospital discharges and improve NHS productivity through increased investments and collaborative initiatives with social care partners. Additionally, the statement from Mr. Trump’s healthcare chief praised the UK-US agreement for promoting innovation in medicine and rebalancing pharmaceutical trade between the two nations, attributing the success to President Trump’s leadership.
Please note: This revised article has been optimized for search engines while maintaining accuracy and readability for readers.